Shareholders’ influence is exercised at the Annual General Meeting, which is Isofol’s highest decision-making body and in which all shareholders have the right to participate. Shareholders who wish to participate in a general meeting, personally or through a representative, shall be admitted to the shareholders’ register held by Euroclear Sweden AB five weekdays before the Annual General Meeting and make a notification to the Company as per the notice. Notice of Annual General Meeting is made through advertising and via the company’s website (www.isofol.se). Annual General Meeting shall be held within six months from the end of the financial year. At the Annual General Meeting, one share entitles one vote. At the Annual General Meeting, each voter may vote for the full number of shares held and represented without restriction in voting rights.
The AGM decides on changes to the articles of association, elects the chairman, the board of directors and auditors, determines the accounts, decides on any dividend and other disposals of the result and discharge from the Board. In addition, the AGM decides on guidelines for salary and other remuneration to senior executives, possible new issues and how the Nomination Committee is to be appointed.
Shareholders wishing to submit a proposal to Isofol’s Nomination Committee 2018 may contact the Nomination Committee by e-mail, email@example.com or at the address: Isofol Medical AB, Att: Valberedningen, Arvid Wallgrens Backe 20, 413 46 Göteborg, Sweden.
Isofol Medical AB´s Extra Ordinary General Meeting will be hold on October 11, 2018, at Isofol Medical AB, Biotech Center, Arvid Wallgrens Backe 20, 413 46 Göteborg.